We propose that B2M testing is a useful adjunct to routine MMR testing and should be incorporated into a bowel tumour‐specific assay in conjunction with MLH1, KRAS, NRAS and BRAF status to provide an overall recurrence risk for individual patients. The gene discussed is NRAS; the disease is neoplasm.